142 related articles for article (PubMed ID: 38036107)
21. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma.
Chen LC; Yang PC; Chen CY; Chiang SF; Chen TW; Chen WT; Ke TW; Liang JA; Shiau AC; Chao KSC; Huang KC
J Cancer; 2024; 15(6):1750-1761. PubMed ID: 38370387
[TBL] [Abstract][Full Text] [Related]
22. Serum miR-1301-3p, miR-335-5p, miR-28-5p, and their target B7-H3 may serve as novel biomarkers for colorectal cancer.
Wang L; Zhao Y; Xu M; Zhou F; Yan J
J BUON; 2019; 24(3):1120-1127. PubMed ID: 31424670
[TBL] [Abstract][Full Text] [Related]
23. B7-H3 regulates KIF15-activated ERK1/2 pathway and contributes to radioresistance in colorectal cancer.
Ma Y; Zhan S; Lu H; Wang R; Xu Y; Zhang G; Cao L; Shi T; Zhang X; Chen W
Cell Death Dis; 2020 Oct; 11(10):824. PubMed ID: 33011740
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer.
Ingebrigtsen VA; Boye K; Tekle C; Nesland JM; Flatmark K; Fodstad O
Int J Cancer; 2012 Dec; 131(11):2528-36. PubMed ID: 22473715
[TBL] [Abstract][Full Text] [Related]
25. B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A.
Ma Y; Wang R; Lu H; Li X; Zhang G; Fu F; Cao L; Zhan S; Wang Z; Deng Z; Shi T; Zhang X; Chen W
J Cancer; 2020; 11(8):2158-2170. PubMed ID: 32127943
[TBL] [Abstract][Full Text] [Related]
26. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
[TBL] [Abstract][Full Text] [Related]
27. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
28. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract][Full Text] [Related]
29. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
31. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
32. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
[TBL] [Abstract][Full Text] [Related]
33. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
Pizon M; Schott DS; Pachmann U; Pachmann K
Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
[TBL] [Abstract][Full Text] [Related]
34. Expression of CYP1B1 and B7-H3 significantly correlates with poor prognosis in colorectal cancer patients.
Liu X; Wang F; Wu J; Zhang T; Liu F; Mao Y; Hua D
Int J Clin Exp Pathol; 2018; 11(5):2654-2664. PubMed ID: 31938380
[TBL] [Abstract][Full Text] [Related]
35. B7-H3 Immune Checkpoint Protein in Human Cancer.
Flem-Karlsen K; Fodstad Ø; Nunes-Xavier CE
Curr Med Chem; 2020; 27(24):4062-4086. PubMed ID: 31099317
[TBL] [Abstract][Full Text] [Related]
36. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis.
Fan H; Zhu JH; Yao XQ
Pak J Med Sci; 2016; 32(6):1568-1573. PubMed ID: 28083066
[TBL] [Abstract][Full Text] [Related]
38. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract][Full Text] [Related]
39. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
40. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
